Cite

HARVARD Citation

    Gonczi, L. et al. (2017). Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort. Inflammatory bowel diseases. 23 (11), p. . [Online]. 
  
Back to record